Glorieux Griet, Mullen William, Duranton Flore, Filip Szymon, Gayrard Nathalie, Husi Holger, Schepers Eva, Neirynck Nathalie, Schanstra Joost P, Jankowski Joachim, Mischak Harald, Argilés Àngel, Vanholder Raymond, Vlahou Antonia, Klein Julie
Nephrology Section, Ghent University Hospital, Gent, Belgium.
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Nephrol Dial Transplant. 2015 Nov;30(11):1842-52. doi: 10.1093/ndt/gfv254. Epub 2015 Jul 9.
The reduced glomerular filtration rate in the advanced stages of chronic kidney disease (CKD) leads to plasma accumulation of uraemic retention solutes including proteins. It has been hypothesized that these changes may, at least in part, be responsible for CKD-associated morbidity and mortality. However, most studies focused on the role of individual proteins, while a holistic, large-scale, integrative approach may generate significant additional insight.
In a discovery study, we analysed the plasma proteome of patients with stage 2-3 CKD (n = 14) and stage 5 CKD with haemodialysis (HD) (n = 15), using high-resolution LC-MS/MS analysis. Selected results were validated in a cohort of 40 patients with different CKD stages with or without HD, using ELISA.
Of a total of 2054 detected proteins, 127 displayed lower, while 206 displayed higher abundance in the plasma of patients on HD. Molecular pathway analysis confirmed the modification of known processes involved in CKD complications, including decreased haemostasis and increased inflammation, complement activation and vascular damage. In addition, we identified the plasma increase during CKD progression of lysozyme C and leucine-rich alpha-2 glycoprotein, two proteins related to vascular damage and heart failure. High level of leucine-rich alpha-2 glycoprotein was associated with higher mortality in stage 5 CKD patients on HD.
This study provides for the first time a comprehensive assessment of CKD plasma proteome, contributing to new knowledge and potential markers of CKD. These results will serve as a basis for future studies investigating the relevance of these molecules in CKD associated morbidity and mortality.
慢性肾脏病(CKD)晚期肾小球滤过率降低导致包括蛋白质在内的尿毒症潴留溶质在血浆中蓄积。据推测,这些变化可能至少部分地导致了与CKD相关的发病率和死亡率。然而,大多数研究集中在单个蛋白质的作用上,而整体的、大规模的、综合的方法可能会产生更多重要的见解。
在一项探索性研究中,我们使用高分辨率液相色谱-串联质谱分析法分析了2-3期CKD患者(n = 14)和接受血液透析(HD)的5期CKD患者(n = 15)的血浆蛋白质组。选定的结果在40例不同CKD阶段、有或无HD的患者队列中使用酶联免疫吸附测定法进行了验证。
在总共检测到的2054种蛋白质中,127种在HD患者血浆中的丰度较低,而206种丰度较高。分子通路分析证实了参与CKD并发症的已知过程发生了改变,包括止血减少、炎症增加、补体激活和血管损伤。此外,我们确定了在CKD进展过程中溶菌酶C和富含亮氨酸的α-2糖蛋白在血浆中的增加,这两种蛋白质与血管损伤和心力衰竭有关。富含亮氨酸的α-2糖蛋白水平升高与接受HD的5期CKD患者较高的死亡率相关。
本研究首次对CKD血浆蛋白质组进行了全面评估,为CKD的新知识和潜在标志物做出了贡献。这些结果将作为未来研究这些分子在CKD相关发病率和死亡率中的相关性的基础。